We are seeking to appoint a Research Associate to join the McEwan Group at the UK Dementia Research Institute at the University of Cambridge.
The post is a fixed term study in collaboration with the ARUK Drug Discovery Institute.
The successful candidate will research the ability of E3 ubiquitin ligases to degrade cytosolic protein aggregates in neurodegenerative diseases. They will build from recent discoveries that the antiviral receptor TRIM21 can evoke a potent degradation response against tau (Benn et al 2024 39208111), to uncover the range and requirement of ligases that can drive aggregate responses. Newly identified ligases will become the subject for collaboration with DDI for medicinal chemistry approaches.
The funds for this post are available until 28 February 2027 in the first instance.
Applicants must have (or be close to obtaining) a PhD.
Appointment at Research Associate level is dependent on having a PhD. Those who have submitted but not yet received their PhD will initially be appointed as a Research Assistant (Grade 5, Point 38 £34,132) moving to Research Associate (Grade 7) upon confirmation of your PhD award.
Key details
- Location UK DRI at Cambridge
- Salary: £37,174-£45,413